Bittium is a Finnish technology company specializing in the development of reliable, secure communications, connectivity solutions, and healthcare technology products and services. We provide medical technology products and services for biosignal measuring in the areas of cardiology and neurology.

Please visit their website to learn more:


Boehringer Ingelheim has 100 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.”

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Learn more at


Broncus Medical, Inc.® is a publicly traded global healthcare company. The Company’s mission is to establish bronchoscopic diagnostic and therapeutic solutions as the gold standard for the diagnosis and treatment of lung disease. Our vision is to be a global leader in the transformation of lung disease treatment.

As a leader in the diagnosis and treatment of lung disease, Broncus Medical continues to partner with clinicians from around the world to answer the biggest challenges in pulmonary medicine through innovative solutions.

The Archimedes® system is a next-generation virtual bronchoscopic navigation system developed from years of experience and clinical feedback. Archimedes integrates CT, pattern recognition software, and fused fluoroscopy to provide real-time airway navigation and Bronchoscopic Trans-Parenchymal Nodule Access (BTPNA). The technology combines state-of-the-art nodule, vessel and airway mapping features along with virtual pathway guidance to ensure a safe and efficient airway or BTPNA procedure. The proprietary software and design allow for the use of any bronchoscope and existing off-the-shelf tools during airway navigation and a simple access kit for BTPNA.

Bronchoscopic Thermal Vapor Ablation® (InterVapor® or BTVA®) is a non-surgical and non-implant therapy developed for emphysema. BTVA is a simple, quick, and non-invasive procedure that typically takes less than 15 minutes and can be performed under light sedation. Vapor is delivered through a catheter to the most diseased segments of the lung. The vapor ablates the diseased tissue and the body removes the ablated tissue through the natural healing process. In patients with severe emphysema, vapor ablation of the most diseased segments of the lung may result in clinically meaningful improvement in breathing by increasing pulmonary function.

Broncus Medical continues to innovate and deliver lung solutions globally that improve patients’ lives through early diagnosis and treatment.

Lung Solutions, Better Life™


Setting standards since 1851

As a family-owned and operated business, Erbe develops, manufactures and markets surgical systems for professional use in various medical disciplines all over the world.

Erbe technology leads the market in many countries and is therefore an inherent part of the working processes in the OR. The products are thus helping to provide the best possible treatment for patients. The portfolio comprises devices and instruments for electrosurgery, thermofusion, plasma surgery, cryosurgery and hydrosurgery. By combining these technologies, innovative applications become possible, particularly in general surgery, gastroenterology, gynecology, pulmonology and urology.

Erbe employs more than 1000 people worldwide, over 650 of them in Germany. Approx. 170 employees work in research and development. The intensive collaboration with renowned users from medical schools and hospitals is the key to success with which Erbe successfully furthers developments in medicine.

Visit their website:


FUJIFILM Healthcare Asia Pacific is a leading provider of innovative diagnostic imaging solutions, dedicated to resolving the evolving challenges of healthcare facilities. Fujifilm innovates for a better world by offering the wide range of cutting-edge technologies & products such as, Magnetic Resonance, Computed Tomography, X-Ray, Endoscopy, Mammography, Ultrasound systems, In Vitro Diagnostics, Veterinary Diagnostics and Medical Informatics to elevate diagnostic confidence, improve efficiency, and support clinicians in providing the best patient care.

FUJIFILM has been leading the advancement of Endoscopy, delivering more than a dozen new state-of-the-art innovations, and offering unmatched levels of image clarity and performance. Our commitment to delivering unparalleled levels of clarity and functionality enables us to cater to a wide range of diagnostic and therapeutic endoscopic needs and empowering endoscopists to reimagine innovation in their practice and get the most from their investment.

Bronchoscopy has become an essential tool for healthcare practitioners to diagnose and manage patients with lung diseases. Bronchoscopy is performed via flexible or rigid bronchoscope. It plays an important role in examination of the bronchus, preliminary diagnosis and therapeutic procedures.

In the field of bronchoscopy, Fujifilm strives to provide the best quality tools for our pulmonologist utilising our imaging technology – (LCI & BLI) & ultrasound for high quality images. With combination of its flexible bronchoscope; slim distal diameter for patient comfort and deeper penetration with ergonomic handle for physicians to improve accuracy & efficiency in bronchoscopic procedures.

As a total healthcare company, Fujifilm is committed to improving lives and promoting a healthier society through enabling early disease detection and contributing to the advancement of healthcare.


Glenmark Pharmaceuticals Ltd. is an innovation‐driven, global pharmaceutical company. Over the past 45 years, we have built a global business spanning 80 countries in the Branded Generics, Generics, Specialty and OTC segments; with a robust presence in Dermatology, Respiratory and Oncology.

Our R&D investments drive the development of novel medicines for health conditions with substantial unmet needs. We also continue to launch generic versions of innovator molecules that improve the standard of affordable treatment. Our approach to innovation has always set us apart and our work in more than two decades speaks for itself. Ryaltris®, for instance, a novel fixed-dose combination for allergic rhinitis has been launched in over 20 markets across the globe.

For Glenmark, sustainability is part of a process encompassing our operations, stakeholders, communities and the planet at large. Through our CSR interventions, we have impacted over 2.6 million lives over the last decade. | Glenmark Pharmaceuticals| glenmark_pharma


Hyphens Pharma is a specialty pharmaceutical and consumer healthcare group headquartered in Singapore. We operate in Southeast Asia and provides a wide range of healthcare products and services, including pharmaceuticals, medical devices, and over-the-counter products. We have established partnerships with leading pharmaceutical companies globally, allowing us to bring a wide range of high-quality products to the Southeast Asian market.

Our portfolio includes both prescription and over-the-counter medications, as well as medical devices and healthcare services. One of our key products for the respiratory diseases is Erdomed®, which is the latest-generation mucolytic and is also a proven adjunct therapy in the management of COPD (Chronic Obstructive Pulmonary Disease) recognized by the GOLD Guidelines.

Hyphens Pharma is committed to providing high-quality products and services that meet the evolving needs of patients and healthcare professionals in the region.

Find out more about us at


I:Emedics Pte Ltd is a medical device distributor based in Singapore, established in 2005. With a focus on Anaesthesiology, ENT, Respiratory, and Wound Care products, we are committed to providing high-quality medical devices to the healthcare industry in Singapore.

Our mission is to make a difference in people’s lives by providing innovative medical products that improve patient outcomes. We work with leading manufacturers worldwide to bring the latest medical technology to healthcare professionals in Singapore.

At I:Emedics, we pride ourselves on our commitment to customer service. We work closely with our customers to understand their needs and provide customized solutions that meet their unique requirements. Our team of experienced professionals is dedicated to providing exceptional service and support, from product training to technical assistance and after-sales service.


Intuitive was founded in 1995 to create innovative, robotic-assisted systems that help empower doctors and hospitals to make surgery less invasive than an open approach. Since da Vinci® became one of the first robotic-assisted systems cleared by the FDA for general laparoscopic surgery, it’s taken robotic-assisted surgery from concept to reality. Working with doctors and hospitals, we’re continuing to develop new, minimally invasive surgical platforms and future diagnostic tools to help solve complex healthcare challenges around the world. Innovating for minimally invasive care.

The Ion endoluminal system is Intuitive’s robotic-assisted platform for minimally invasive biopsy in the lung. We built Ion on the belief that collecting lung tissue samples for biopsy could be safe and simple, even when nodules are small and located in the peripheral lung. The Ion experience starts with PlanPoint software that translates a CT scan of the patient’s lung, building a 3D model to map a pathway to the nodules that need biopsy. Using this detailed map, a physician can use the simple scroll wheel and trackball to drive the ultra-thin robotic catheter into the lung during the procedure. Ion’s ultrathin 3.5 millimeter diameter, fully articulating catheter bends 180 degrees in any direction as needed. This enables doctors to reach deep into lungs in order to obtain a tissue sample to aid diagnosis. Fiber-optic based shape-sensing technology measures the location of the catheter hundreds of times a second, providing the physician with real-time guidance. This technology enables Ion to hold the catheter in a fixed position for passage of biopsy tools in place, such as Intuitive’s Flexision Biopsy Needle. And its unprecedented stability enables the precision needed for biopsy. Improving precision and efficiency is at the core of our intent with Ion.

Through listening to and learning from our customers, we continuously refine the system—to keep Ion at the forefront of what’s possible. Intuitive’s robotic-assisted surgical products have been used in more than 8.5 million procedures globally. Ion represents an expansion of minimally invasive care to potentially aid the patient journey for the one of the most prevalent cancers in the world.

The Journal of Thoracic Disease

The Journal of Thoracic Disease (JTD, J Thorac Dis, pISSN: 2072-1439; eISSN: 2077-6624) is a monthly, international, peer-reviewed, open-access journal, which was founded in Dec 2009. JTD is indexed by Science Citation Index Expanded (SCIE), PubMed/PubMed Central and Scopus. JTD received its impact factor of 2.5 for the year 2022. JTD publishes manuscripts that describe new findings and provide current, practical information on the diagnosis and treatment of conditions related to thoracic diseases, including but not limited to respiratory, lung, heart, esophageal, and mediastinal diseases. All the submission and reviewing are conducted electronically so that rapid review is assured.

JTD is the official publication of China State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health and the First Affiliated Hospital of Guangzhou Medical University.


MacroLux Medical Technology Co., Ltd., a cutting-edge company in the field of medical technology, was established in 2020, strategically located in the innovation hub of Shenzhen, China. With a dedicated team of over one hundred skilled employees, we are committed to developing advanced solutions that enhance patient care and improve healthcare outcomes worldwide.

Our founding team brings together a wealth of experience from leading medical device companies, specializing in endoscope product research and development, sales and marketing, and manufacturing. With a deep understanding of the industry, we are committed to pushing boundaries and driving innovation in the field of endoscopic intervention therapy.

Recognizing the long-term rise of the aging population and an increasing number of cancer cases, we prioritize the development of single-use endoscope products, revolutionizing the approach to minimally invasive procedures. Our dedication to innovation is underscored by our team of experts, which includes experienced professionals in optical and image optimization analysis, mechanical engineering, and other specialized fields.

With our business success in China, we are also expanding our oversea business with FDA and CE certificates. We maintain stringent quality control measures and operate a state-of-the-art factory with a 100,000 Class Clean Area, Microbiology Laboratory, and General Production Workshop, ensuring the highest standards in manufacturing and product quality.

We are working on providing a stronger and smarter total solution, encompassing device and consumable solutions, AI algorithms, and surgical robots. By leveraging cutting-edge technologies, we aim to optimize patient outcomes and streamline medical procedures. Besides, we are committed to globalization and localization as well, with plans to establish local offices in major countries across different regions. We hope to build tight connection with medical workers and patients around the world.


MIMS Education is the ultimate resource for healthcare professionals who want to upskill their clinical knowledge. With nearly 20 specialty topics, you’ll find relevant topics for your interests and clinical care learning needs from various specialized modules available on the platform. More modules are added every month, so you always have the latest content at your fingertips.


O2 Healthcare Group Pte. Ltd. is formed by OUE Healthcare Limited (“OUEH”) and three Singapore medical specialist groups, namely Respiratory Medical Associates (“RMA”), The Respiratory Practice (“TRP”) and Thoracic & Cardiovascular Surgery Specialist (“TCSS”) via the joint venture company with OUE Limited (“OUE”).

At O2 Healthcare Group, our team of senior lung specialists is dedicated to delivering exceptional care, focusing on enhancing the quality of life for our patients. With expertise in cardiac surgery, thoracic surgery, pulmonary medicine, allergy and intensive care, we offer comprehensive and personalised specialist medical services tailored to address a diverse range of lung conditions. As a dynamic alliance of lung specialists, we are leading the way in reshaping respiratory care in Asia with tailored solutions and a patient-focused approach.

Our Purpose: An internationally recognised Lung Centre of choice for expert management of heart and lung conditions.

Our Vision: To provide patient-centric care to individuals with heart and lung conditions, offering personalised solutions rooted in evidence-based clinical excellence while harnessing new technologies for accurate diagnosis, faster healing and recovery.

Our Core Values: Excellence, Compassion, Collaboration, Innovation and Patient-Centric Care.

The medical services we provide encompass all aspects of Respiratory Medicine, Allergy and Cardiothoracic Surgery.

Respiratory Medical Services include but not limited to chronic lung disease management (ie: Asthma, Bronchiectasis, Interstitial Lung Disease & Chronic Obstructive Pulmonary Disease), treatment of  and preventing pulmonary infections (i.e. Pneumonia & Tuberculosis, etc.) and pulmonary intervention (i.e. Bronchoscopy, Lung Biopsy, Endobronchial Ultrasound, Medical Thoracoscopy, Cryobiopsy, Whole Lung Lavage, etc.), Intensive Care Unit Expertise, Allergy Testing and Smoking Cessation, etc.

Cardiothoracic Surgery Services include, but not limited to, Valvular Surgery, Heart Failure Surgery, Arrhythmia Surgery, Cardiac Tumour Resection, Congenital Cardiac Surgery, Aortic Surgery, Peripheral Vascular Surgery, Lung Nodules Surgery, Mediastinal Tumour Surgery, and Heart Bypass Surgery etc.


At Olympus, we are committed to our purpose of making people’s lives healthier, safer and more fulfilling. As a leading medical technology, we are focused on using capabilities in medical technology and precision manufacturing to deliver advanced diagnostic, therapeutic, and minimally invasive procedures to healthcare professionals. In the area of pulmonology, we provide minimally invasive lung cancer solutions that can help improve clinical outcomes in lung cancer diagnosis and staging, reducing overall costs, and enhancing the quality of life for patients.

Olympus’ offers a complete line of bronchoscopes and devices to help pulmonologists in the effective diagnosis and treatment of pulmonary diseases. With the new flagship EVIS X1 processor, there is now new and easy-to-use technologies to help pulmonologists in their detection, characterization and sampling of pulmonary disorders. Together with the new EVIS X1 BF-1100 bronchoscopes and EVIS EXERA III BF-190 bronchoscopes, our range of scopes are designed to improve tracheobronchial access and deliver visibility that is better than ever before.

Endoscopic ultrasound also plays a key role in facilitating the visualization of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for early, minimally invasive diagnosis and lung cancer staging. We offer a full line of endoscopic devices supporting advanced bronchoscopy procedures, including EBUS transbronchial needle aspiration (EBUS TBNA) for visualization during sampling, lymph node staging and  mediastinoscopies.


Sanofi’s unrelenting commitment to scientific exploration extends to immunology, where it has a first-in-class treatment and robust pipeline of potential new medicines for chronic dermatologic, respiratory, and gastrointestinal diseases. Sanofi’s portfolio of medicines includes the first biologic treatment approved for people six to twelve years with severe atopic dermatitis (the most common form of eczema). This medicine is also approved for people 12 years and older with moderate-to-severe atopic dermatitis, moderate-to-severe asthma, and for adults with moderate-to-severe chronic rhinosinusitis with nasal polyps. Sanofi is also studying it in a variety of other type 2 inflammatory diseases, including eosinophilic esophagitis, chronic obstructive pulmonary disease, and more than a half dozen others. In addition to Sanofi’s deep commitment and investment in treating diseases driven by type 2 inflammation, it continues to actively expand its work across other immunological pathways that contribute to a variety of diseases, leveraging new approaches and platform technologies for the benefit of patients.


Teva’s mission is to improve the lives of patients across the globe. We believe that everyone should have access to quality medicines whether it be for managing disease, fighting infections, or simply improving overall health. Teva offers the world’s largest medicine cabinet – a full spectrum of products from generics, API and over-the-counter products to specialty and biologic treatments. We are proud that since Teva’s establishment in 1901, healthcare providers together with patients and caregivers have been using our accessible generic and innovative products. Today, our portfolio of around 3,600 products is among the largest of any pharmaceutical company in the world. Nearly 200 million people in 60 countries benefit from one of Teva’s quality medicines every day. We invest in research and development of generic medicines and biopharmaceuticals, carrying on the legacy of more than a century of finding new ways to help patients improve their lives. This defines our values as a company and characterizes how we do business and approach medicine.

Please visit their website to learn more:


Trudell Medical International is a leading global respiratory medical devices company dedicated to developing patient inspired innovations in aerosol drug delivery and lung health devices for patients around the world. Our commitment to excellence, clinical validation, and the trust of our customers drives our mission to help people Breathe Better and Live Fuller lives. With a celebrated legacy of 40 years of AeroChamber* brand of valved holding chambers and over 100 years as a proud Canadian company, we prioritize putting patients first in all our endeavors.

AeroChamber Plus* Flow-Vu* Anti-Static Valved Holding Chamber:

Supported by hundreds of peer reviewed studies including SmPC listings, and used by patients around the world, the AeroChamber* spacers help make every puff count by enhancing drug delivery efficiency and helping ensure proper inhalation technique to improve disease control and the sustainability of inhaler use.

AeroChamber2go* Chamber:
The newest innovation for all people who need access to their medication on-the-go. AeroChamber2go* spacer is a portable 2-in-1 chamber and protective case for the inhaler that helps provide confidence in drug delivery when away from home.

AeroChamber* brand spacers for Ventilation and Specialty Purposes
A full line of devices for a range of mechanical ventilation options, tracheostomy, and specialty applications in clinics and hospitals.

Aerobika* Oscillating Positive Expiratory Pressure (OPEP) Device
Designed to help mobilize and clear mucus secretions from the airways to reduce the risk of exacerbations and improve lung function. It’s unique pressure oscillation profile, ease of use for patients, and optional manometer trainer and nebulizer connectivity, help make it an optimal airway clearance solution for respiratory conditions such as COPD and bronchiectasis.

AeroEclipse* BAN* Nebulizers
Innovative breath actuated technology delivers medication only during inhalation, helping maximize lung deposition, improve dose consistency, minimize waste, and limit exposure to nearby patients and staff.

Please visit their website to learn more:


Virology Education is committed to facilitating medical education to healthcare professionals in the fields of HIV, hepatitis, COVID-19, oncology, and more to develop these disciplines and support communities with continuing education. With this clear mission and drive to keep education accessible and inclusive to all professionals who wish to participate, we operate all over the world and produce medical programs in English, Spanish, Portuguese, Mandarin Chinese, Russian, among several other languages. We strive to have a diverse and informed group of speakers and participants to enable knowledge sharing and networking across various fields and specialties. By including speakers and engaging participants from all ethnicities, ages, geographic locations, and genders, we aim to ensure that the knowledge disseminated in our programs is all-encompassing, meeting the wide-ranging needs of the global healthcare community.
As we continue to develop our portfolio of medical education programs, our goal is to revisit our curricula to ensure that each program’s primary focus is to address the most urgent medical education needs and simultaneously assess the delivery format to ensure the greatest impact. With this winning combination of learning from our feedback and leveraging our network of key opinion leaders, we strive to derive the highest-quality content into concise but comprehensive learning via online education, hybrid meetings for small and large groups, and enduring materials.

For more information, please visit our website here:


Vyaire Medical Inc. is a global company, headquartered in suburban Chicago, focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 65-year history of pioneering breathing technology, the company’s portfolio of integrated solutions is designed to enable, enhance, and extend lives.

At Vyaire, our team of 4,000, pledges to advance innovation and evolve what’s possible to ensure every breath is taken to its fullest. Vyaire’s products are available in more than 100 countries and are recognized, trusted, and preferred by specialists throughout the respiratory community worldwide.